Investigational drug · Phase 2
JL18008
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for HIV Infections.
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "JL18008"
First trial start
2026
May 26, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "JL18008", any sponsor or status.
Conditions studied
As listed on its trial records.
- HIV Infections
Approved drugs for the same conditions: Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "JL18008" as an intervention, largest first.
- Recombinant Human Interleukin-7 (JL18008) for the Treatment of HIV-Infected Immunological Non-RespondersNot yet recruiting
Jecho Biopharmaceuticals Co., Ltd.Industry
NCT07443228 · 52 participants (planned) · Start May 30, 2026 · Primary completion Dec 20, 2029
Drug: JL18008 · For: HIV
- To Evaluate the Safety of JL18008Completed
Jecho Biopharmaceuticals Co., Ltd.Industry
NCT07629310 · 40 participants · Start Jun 13, 2024 · Primary completion Aug 5, 2025
Drug: JL18008 1 μg/kg; JL18008 5 μg/kg and 10 more · For: HIV Infections
Sites: Beijing, China
Jecho Biopharmaceuticals Co., Ltd.Industry
NCT07579741 · 30 participants (planned) · Start May 26, 2026 · Primary completion Feb 12, 2027
Drug: JL18008 20 μg/kg; Placebo (for 20 μg/kg Group) and 4 more · For: HIV Infections
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for HIV Infections
- rHuPH20Phase 35 trials
Bristol Myers Squibb · Melanoma, Relapsing-remitting Multiple Sclerosis, Clear Cell Renal Cell Carcinoma
- TeropavimabTAB, GS-5423Phase 33 trials
Gilead Sciences · HIV-1 Infection, HIV Infections, HIV-1-infection
- ZinlirvimabGS-2872, ZABPhase 33 trials
Gilead Sciences · HIV-1 Infection, HIV Infections, HIV-1-infection
- 2 NRTIsPhase 32 trials
Merck & Co. · Human Immunodeficiency Virus (HIV) Infection, Infection, Human Immunodeficiency Virus, HIV Infections
- ABC3TC STR, 3TC immediate releasePhase 32 trials
GSK · HIV Infections
- ARTPhase 32 trials
GSK · HIV Infections, HIV-1 Infection
- DTGPhase 32 trials
Jiangsu Aidea Pharmaceutical Group Co., Ltd. · Infection, Human Immunodeficiency Virus, HIV Infections
- BMS-663068Phase 31 trial
GSK · HIV Infections
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.